Tamoxifen for Early Breast Cancer
Author Information
Author(s): M. Baum, D.M. Brinkley, J.A. Dosset, K. McPherson, I.M. Jackson, R.D. Rubens, F.G. Smiddy, B.A. Stoll, A.J. Wilson, I.H. Birch, M.K. Palmer
Primary Institution: Kings College Hospital
Hypothesis
Does adjuvant tamoxifen therapy improve outcomes in early breast cancer patients compared to no treatment?
Conclusion
Adjuvant tamoxifen therapy significantly reduces the risk of events and deaths in early breast cancer patients.
Supporting Evidence
- Tamoxifen treated patients had a 36% reduction in risk of events.
- Tamoxifen treatment resulted in a 29% reduction in risk of death.
- Significant reduction in local recurrences was observed in tamoxifen treated patients.
- No evidence that tamoxifen increased deaths from causes other than cancer.
Takeaway
Taking tamoxifen after breast cancer surgery helps patients live longer and have fewer problems.
Methodology
Patients were randomized to receive tamoxifen or no treatment after surgery, with follow-up for events and deaths.
Potential Biases
No significant interaction between treatment effects and prognostic variables was detected.
Limitations
Quality control between laboratories was not part of the study.
Participant Demographics
Patients aged 75 years or less, with node positive status determined by sampling.
Statistical Information
P-Value
0.0001
Confidence Interval
(0.53, 0.77)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website